Our platform represents a milestone in the combat of toxic shock and a major advance since the exploration of Penicillin in 1928…

Phase ii

After 25 years of own financed research and pilot scale vaccine production, our patented vaccine platform is ready to fight toxins of multiple gram-positive and gram-negative bacteria.

The Staphylococcal TSST-1 vaccine successfully passed a Phase II clinical dose escalation study and exceeded the expectations of immunological endpoints.

A pipeline of additional vaccine candidates is under development to build a multi-component vaccine for prevention of Toxic Shock.


The WHO made Sepsis a global health priority, by adopting a resolution to improve, prevent, diagnose, and manage sepsis. Sepsis associated with 1 in every 5 death worldwide, 48.9 million cases annually.  It is the leading cause of death in burn patients, which is the most common cause of unexpected mortality in children with small burns.